Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
anti-CEA CAR-M
- Development stage
- Preclinical
- Lead developer
- Shoreline Biosciences
- Modality
- iPSCs → Pluripotent Stem Cells → Stem Cell Therapies → Cell Therapies
- Administration
- Intravenous
01
Overview
anti-CEA CAR-M is an investigational, allogeneic chimeric antigen receptor macrophage (CAR-M) therapy being developed by Shoreline Biosciences for the treatment of CEA-expressing solid tumors. Unlike autologous CAR-Ms derived from patient monocytes, this candidate is engineered from renewable cell sources, including induced pluripotent stem cells (iPSCs) and umbilical cord blood-derived CD34+ hematopoietic stem cells (CB-HSCs), using a standardized manufacturing platform. The cells are transduced with a lentiviral vector encoding a second-generation CAR that targets Carcinoembryonic Antigen (CEA) and incorporates unique intracellular signaling domains designed to promote and sustain a pro-inflammatory M1 phenotype. Upon binding to CEA-positive tumor cells, the CAR-Ms trigger antigen-specific phagocytosis and release pro-inflammatory cytokines, potentially overcoming the immunosuppressive microenvironment of solid tumors.
- Other names
- CEA-targeted CAR-MiPSC-derived anti-CEA CAR-MCB-HSC-derived anti-CEA CAR-M
02
Targets
CEACAM5 (Carcinoembryonic antigen related cell adhesion molecule 5)
Beyond the preview
Go deeper on anti-CEA CAR-M.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on anti-CEA CAR-M.